The US FDA has granted priority review status to the NDA for InterMune's idiopathic pulmonary fibrosis (IPF) candidate pirfenidone.
This move gives the potential to accelerate the drug's approval by reducing the targeted review period from 10 months to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?